A systemic apolipoprotein A-IV-associated amyloidosis confirmed by proteome analysis

Taro Murakami1, Akira Takasawa1, Asako Moriki1,2, Yusuke Igaki3, Hiroshi Ikeda4, Kazuyuki Murase4, Kohichi Takada4, Kazufumi Magara1, Tomoyuki Aoyama1, Yusuke Ono1, Daisuke Kyuno1, Kumi Takasawa1, Masaki Murata1,5, Makoto Osanai1
1Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
2Department of Hematology, Hokkaido University Hospital, Sapporo, Japan;
3Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
4Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan
5Department of Pathology, Hokkaido Ohno Memorial Hospital, Sapporo, Japan

Tóm tắt

Amyloidosis is induced by extracellular deposition of certain proteins. Thirty-six proteins have so far been identified as amyloidogenic proteins in humans. Although it is very important to determine the specific amyloid protein type for the choice of therapy for amyloidosis patient, it might be difficult to identify specific proteins from amyloid-deposited tissue. Apolipoprotein A-IV is known as an amyloid-associated protein, but there have been few reports of apolipoprotein A-IV amyloidosis. Here we report a case of systemic apolipoprotein A-IV-associated amyloidosis that was confirmed by proteome analysis using formalin-fixed paraffin-embedded tissue and an immunohistochemical technique.

Tài liệu tham khảo

Dasari S, Amin MS, Kurtin PJ, Vrana JA, Theis JD, Grogg KL, Alexander MP, Nasr SH, Fervenza FC, Leung N, Sethi S (2016) Clinical biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis. Kidney Int 90(3):658–664. https://doi.org/10.1016/j.kint.2016.04.003 Wechalekar AD, Gillmore JD, Hawkins PN (2016) Systemic amyloidosis. Lancet 387(10038):2641–2654. https://doi.org/10.1016/S0140-6736(15)01274-X Picken MM (2020) The pathology of amyloidosis in classification: a review. Acta Haematol 11:1–13. https://doi.org/10.1159/000506696 Mollee P, Renaut P, Gottlieb D, Goodman H (2014) How to diagnose amyloidosis. Intern Med J 44(1):7–17. https://doi.org/10.1111/imj.12288 Nienhuis HL, Bijzet J, Hazenberg BP (2016) The prevalence and management of systemic amyloidosis in western countries. Kidney Dis 2(1):10–19. https://doi.org/10.1159/000444206 Naiki H, Sekijima Y, Ueda M, Ohashi K, Hoshii Y, Shimoda M, Ando Y (2020) Human amyloidosis, still intractable but becoming curable: the essential role of pathological diagnosis in the selection of type-specific therapeutics. Pathol Int 70(4):191–198. https://doi.org/10.1111/pin.12902 Winter M, Tholey A, Kristen A, Röcken C (2017) MALDI mass spectrometry imaging: a novel tool for the identification and classification of amyloidosis. Proteomics 17(22):1700236. https://doi.org/10.1002/pmic.201700236 Aoyama T, Takasawa A, Murata M, Osanai M, Takano K, Hasagawa T, Sawada N (2019) Immunoreactivity patterns of tight junction proteins are useful for differential diagnosis of human salivary gland tumors. Med Mol Morphol 52(1):23–35. https://doi.org/10.1007/s00795-018-0199-6 Saito Y, Takasawa A, Takasawa K, Aoyama T, Akimoto T, Ota M, Magara K, Murata M, Hirohashi Y, Hasegawa T, Sawada N, Saito T, Osanai M (2020) Aldolase A promotes epithelial-mesenchymal transition to increase malignant potentials of cervical adenocarcinoma. Cancer Sci 111(8):3071–3081. https://doi.org/10.1111/cas.14524 Qu J, Ko CW, Tso P, Bhargava A (2019) Apolipoprotein A-IV: a multifunctional protein involved in protection against atherosclerosis and diabetes. Cells 8(4):E319. https://doi.org/10.3390/cells8040319 Bergström J, Murphy C, Eulitz M, Weiss DT, Westermark GT, Solomon A, Westermark P (2001) Codeposition of apolipoprotein A-IV and transthyretin in senile systemic (ATTR) amyloidosis. Biochem Biophys Res Commun 285(4):903–908. https://doi.org/10.1006/bbrc.2001.5260 Sethi S, Theis JD, Shiller SM, Nast CC, Harrison D, Rennke HG, Vrana JA, Dogan A (2012) Medullary amyloidosis associated with apolipoprotein A-IV deposition. Kidney Int 81(2):201–206. https://doi.org/10.1038/ki.2011.316 Bergström J, Murphy CL, Weiss DT, Solomon A, Sletten K, Hellman U, Westermark P (2004) Two different types of amyloid deposits--apolipoprotein A-IV and transthyretin--in a patient with systemic amyloidosis. Lab Investig 84(8):981–988. https://doi.org/10.1038/labinvest.3700124 Bois MC, Dasari S, Mills JR, Theis J, Highsmith WE, Vrana JA, Grogan M, Dispenzieri A, Kurtin PJ, Maleszewski JJ (2017) Apolipoprotein A-IV-associated cardiac amyloidosis. J Am Coll Cardiol 69(17):2248–2249. https://doi.org/10.1016/j.jacc.2017.02.047 Martins E, Urbano J, Leite S, Pinto A, Garcia R, Bergantim R, Rodrigues-Pereira P, Costa PP, Osório H, Tavares I (2019) Cardiac amyloidosis associated with apolipoprotein A-IV deposition diagnosed by mass spectrometry-based proteomic analysis. Eur J Case Rep Intern Med 6(12):001237. https://doi.org/10.12890/2019_001237